All tags Neuroscience Targeting axonal transport in Alzheimer's disease webinar

Targeting axonal transport in Alzheimer's disease webinar

What makes a good potential target for drug discovery? 

Listen in as  Dr Elizabeth Glennon, of King's College London, discusses how the disruption of axonal transports early on within Alzheimer's Disease provides excellent targets for drug discovery.

48:13
48:13
Wistia video thumbnail - Targeting axonal transport in Alzheimer's disease

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message
Enter your email to view for free
By entering your email you get free updates about relevant events, access to our
library of webinars, resource videos and research tools. We respect your privacy
and you can unsubscribe at any time from marketing communications.
Error text
 
 

Webinar topics:

  • How disruption of axonal transport contributes to the development of Alzheimer's disease
  • Mechanisms of axonal transport of the Alzheimer's amyloid precursor protein, and how these are altered in the disease

Meet our presenter

Elizabeth (Lizzie) Glennon studied her degree in biochemistry at the University of York (UK), followed by a PhD at the Univeristy of Leeds (UK), where she studied molecular mechanisms of neurodegeneration in Alzheimer's disease.  Lizzie subsequently moved to King's College London, where she worked as a post doc investigating how a break down in axonal transport may contribute to development of Alzheimers disease.  

Lizzie is now an Alzheimer's Research UK fellow at the Institute of Psychiatry, Psychology and Neuroscience at King's College London, where she is investigating how genes linked to Alzheimer's disease could affect the subcellular trafficking of the AD hallmark protein tau.